...Ilypsa Inc. subsidiary to bixalomer to treat hyperphosphatemia (see BioCentury, May 1, 2006). Astellas and Sanwa Kagaku Kenkyusho Co. Ltd....

...Ilypsa Inc. subsidiary to Kiklin to treat hyperphosphatemia (see BioCentury, May 1, 2006). Astellas and Sanwa Kagaku Kenkyusho Co. Ltd....

...Ilypsa Inc. subsidiary to Kiklin to treat hyperphosphatemia (see BioCentury, May 1, 2006). Astellas and Sanwa Kagaku Kenkyusho Co. Ltd....

...the product through its 2003 acquisition of Oculex Pharmaceuticals Inc. (see BioCentury, Oct. 20, 2003). Sanwa...
...under a 2005 deal (see BioCentury, April 4, 2005). Allergan Inc . (NYSE:AGN), Irvine, Calif. Sanwa Kagaku Kenkyusho Co. Ltd....

...the product through its 2003 acquisition of Oculex Pharmaceuticals Inc. (see BioCentury, Oct. 20, 2003). Sanwa...
...Japan under a 2005 deal (see BioCentury, April 4, 2005). Allergan Inc. (NYSE:AGN), Irvine, Calif. Sanwa Kagaku Kenkyusho Co. Ltd....

...Terrapin and Sanwa will use Terrapin's TRAP molecular fingerprinting technology to develop compounds to treat diabetes...
...million in license fees, R&D funding, milestones and equity investments, and is eligible for royalties. Sanwa...
...use the TRAP technology to screen for compounds to treat other diseases of interest to Sanwa...

...products. Astellas said that in January it launched Argamate Granule calcium polystyrene sulfonate with partner Sanwa Kagaku Kenkyusho Co. Ltd....
...treat hyperkalemia. The companies partnered in February 2012 to co-promote the product, which consist of Sanwa's...

...the indication under a 2007 deal with Ilypsa (see BioCentury, May 1, 2006). Astellas and Sanwa Kagaku Kenkyusho Co. Ltd....

...4SC's 4SC Discovery GmbH subsidiary received a undisclosed milestone payment from Sanwa under a 2005 deal...
...technology to identify candidates against two metabolic targets from Sanwa. The payment was triggered by Sanwa...
...deal. Details were not disclosed (see BioCentury, Feb. 21, 2005). 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Sanwa Kagaku Kenkyusho Co. Ltd....

...and Sanwa partnered to co-promote Sanwa's 20% Argamate calcium polystyrene sulfonate jelly and Astellas' bixalomer. Sanwa...
...with chronic kidney disease in March 2011. Sanwa will manufacture and supply Argamate to Astellas. Sanwa...
...of ¥6-7 billion ($75.6-88.2 million). Terms were not disclosed. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Sanwa Kagaku Kenkyusho Co. Ltd....